DNA Script

Executive Summary

DNA Script is a private French biotechnology company pioneering enzymatic DNA synthesis technology. Its proprietary SYNTAX® DNA printer leverages advanced enzymatic methods to produce longer, more complex DNA sequences than traditional chemical synthesis, enabling breakthroughs in synthetic biology, genomics, and drug discovery. Founded in 2014 and headquartered in Paris, DNA Script has established itself as a key player in the DNA synthesis market, offering faster, more accurate, and environmentally sustainable alternatives for researchers. The company's technology addresses critical bottlenecks in gene synthesis and assembly, positioning it for adoption across academic and industrial laboratories. With growing demand for custom DNA constructs in therapeutic development and diagnostics, DNA Script's platform has the potential to disrupt the $5 billion+ synthetic biology tools market. While still private, the firm has likely attracted significant venture funding to support commercialization and scale-up of its SYNTAX platform, though exact financials are undisclosed. The combination of innovative enzymology and a user-friendly workflow positions DNA Script for strong traction as the field moves toward enzymatic synthesis as the standard.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch of next-generation SYNTAX system with extended read length capabilities70% success
• Q4 2026Strategic partnership with a major pharmaceutical company for gene synthesis services60% success
• TBDSeries D or later-stage funding round disclosed (valuation and investors)80% success